First published March 2, 2015 - More info
Interactions between the host and gut microbial community likely contribute to Crohn disease (CD) pathogenesis; however, direct evidence for these interactions at the onset of disease is lacking. Here, we characterized the global pattern of ileal gene expression and the ileal microbial community in 359 treatment-naive pediatric patients with CD, patients with ulcerative colitis (UC), and control individuals. We identified core gene expression profiles and microbial communities in the affected CD ilea that are preserved in the unaffected ilea of patients with colon-only CD but not present in those with UC or control individuals; therefore, this signature is specific to CD and independent of clinical inflammation. An abnormal increase of antimicrobial dual oxidase (
Yael Haberman, Timothy L. Tickle, Phillip J. Dexheimer, Mi-Ok Kim, Dora Tang, Rebekah Karns, Robert N. Baldassano, Joshua D. Noe, Joel Rosh, James Markowitz, Melvin B. Heyman, Anne M. Griffiths, Wallace V. Crandall, David R. Mack, Susan S. Baker, Curtis Huttenhower, David J. Keljo, Jeffrey S. Hyams, Subra Kugathasan, Thomas D. Walters, Bruce Aronow, Ramnik J. Xavier, Dirk Gevers, Lee A. Denson
Original citation: J Clin Invest. 2014;124(8):3617–3633. doi:10.1172/JCI75436.
Citation for this corrigendum: J Clin Invest. 2015;125(3):1363. doi:10.1172/JCI79657.
The authors recently completed an additional sample quality control process for the RNA-sequencing (RNA-seq) data reported in the manuscript that involved matching base calling from the RNA-seq data to the associated genotyping data and clinical metadata for each subject. This process identified 55 RNA-seq data files that were not linked to the correct clinical metadata. For 41 RNA-seq data files, the relabeling occurred within Crohn disease (CD) cases. For 6 files, the relabeling resulted in a change in diagnosis from ulcerative colitis (UC) to CD, while for 6 files, the relabeling resulted in a change in diagnosis from CD to UC. One file was relabeled within the non– inflammatory bowel diseases (non-IBD) control group, and for 1 file, relabeling resulted in a change from CD to non-IBD control. In addition, the authors identified 13 cases of sample duplication, 7 cases of African American race or IBD-undefined (IBD-U) diagnosis, and 20 cases in which the link between the RNA-seq data, genotype data, and clinical metadata could not be confirmed because of uncertain base calling. This included 26 CD cases, 12 UC cases, and 2 non-IBD control cases that must be excluded from the analysis. The data set for NCBI’s Gene Expression Omnibus (GEO GSE57945) has been updated to reflect these changes. In addition, revised versions of Supplemental Table 3, Supplemental Table 12, and Supplemental Table 13 have been updated online. A revised version of Table 1 is below.
RISK RNA-seq cohort clinical and demographic characteristics
Correction of the mislabeling did not result in a significant difference in the clinical and demographic features of the cohort (Table 1). Following the correction, 1,159 of 1,281 (90%) genes from the original publication for the core ileal CD (iCD) gene list (Supplemental Table 3) were still determined to be significantly and differentially expressed between 2 independent groups of iCD versus control; 155 of 179 (87%) genes from the publication for the colon-only CD (cCD) versus UC gene list (Supplemental Table 12) were still determined to be significantly and differentially expressed between cCD and UC; and 342 of 345 (99%) genes from the publication for the iCD without deep ulcers (iCD-noDU) versus iCD with deep ulcers (iCD-DU) gene list (Supplemental Table 13) were still determined to be significantly and differentially expressed between iCD-noDU and iCD-DU. This included upregulation of DUOX2 and suppression of APOA1 within the top 5 up- and downregulated genes within the core ileal CD gene list and maximal suppression of APOA1 within the cCD versus UC comparison and the iCD-DU versus iCD-noDU comparison.
The authors regret the errors.